These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38750558)

  • 1. Proof of stability of an RSV Controlled Human Infection Model challenge agent.
    Verstraelen S; Roymans D; Jacobs A; Hollanders K; Remy S; Jochmans D; Klein J; Grauwet T
    Virol J; 2024 May; 21(1):112. PubMed ID: 38750558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sucrose stabilization of Respiratory Syncytial Virus (RSV) during nebulization and experimental infection.
    Grosz DD; van Geelen A; Gallup JM; Hostetter SJ; Derscheid RJ; Ackermann MR
    BMC Res Notes; 2014 Mar; 7():158. PubMed ID: 24642084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of Respiratory Syncytial Virus (RSV) Memphis Strain 37 (M37) Infection in the Respiratory Tract of Newborn Lambs as an RSV Infection Model for Human Infants.
    Larios Mora A; Detalle L; Van Geelen A; Davis MS; Stohr T; Gallup JM; Ackermann MR
    PLoS One; 2015; 10(12):e0143580. PubMed ID: 26641081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats.
    Green G; Johnson SM; Costello H; Brakel K; Harder O; Oomens AG; Peeples ME; Moulton HM; Niewiesk S
    J Virol; 2021 Jul; 95(16):e0001021. PubMed ID: 34037420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the role of respiratory syncytial virus surface glycoproteins F and G on viral stability and replication: implications for future vaccine design.
    DeFord DM; Nosek JM; Castiglia KR; Hasik EF; Franke ME; Nick BC; Abdelnour AM; Haas CE; Junod NA; Latsko KN; Moore ML; Berthrong ST; Rostad CA; Stobart CC
    J Gen Virol; 2019 Jul; 100(7):1112-1122. PubMed ID: 31184573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.
    Xue M; Wang R; Harder O; Chen P; Lu M; Cai H; Li A; Liang X; Jennings R; La Perle K; Niewiesk S; Peeples ME; Li J
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of consistency in quantification of gene copy number by real-time reverse transcription quantitative polymerase chain reaction and virus titer by plaque-forming assay for human respiratory syncytial virus.
    Yamamoto K; Ogasawara N; Yamamoto S; Takano K; Shiraishi T; Sato T; Tsutsumi H; Himi T; Yokota SI
    Microbiol Immunol; 2018 Feb; 62(2):90-98. PubMed ID: 29266482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.
    Boyoglu-Barnum S; Todd SO; Meng J; Barnum TR; Chirkova T; Haynes LM; Jadhao SJ; Tripp RA; Oomens AG; Moore ML; Anderson LJ
    J Virol; 2017 May; 91(10):. PubMed ID: 28275196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
    Liang B; Munir S; Amaro-Carambot E; Surman S; Mackow N; Yang L; Buchholz UJ; Collins PL; Schaap-Nutt A
    J Virol; 2014 Apr; 88(8):4237-50. PubMed ID: 24478424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin.
    Gupta CK; Leszczynski J; Gupta RK; Siber GR
    Vaccine; 1996 Oct; 14(15):1417-20. PubMed ID: 8994316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunostimulatory Defective Viral Genomes from Respiratory Syncytial Virus Promote a Strong Innate Antiviral Response during Infection in Mice and Humans.
    Sun Y; Jain D; Koziol-White CJ; Genoyer E; Gilbert M; Tapia K; Panettieri RA; Hodinka RL; López CB
    PLoS Pathog; 2015 Sep; 11(9):e1005122. PubMed ID: 26336095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
    Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
    J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology.
    Zhang L; Peeples ME; Boucher RC; Collins PL; Pickles RJ
    J Virol; 2002 Jun; 76(11):5654-66. PubMed ID: 11991994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human airway epithelial cell cultures for modeling respiratory syncytial virus infection.
    Pickles RJ
    Curr Top Microbiol Immunol; 2013; 372():371-87. PubMed ID: 24362700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation of Influenza A Virus Disease Severity by Respiratory Syncytial Virus Co-Infection in a Mouse Model.
    George JA; AlShamsi SH; Alhammadi MH; Alsuwaidi AR
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs.
    Salinas FM; Nebreda AD; Vázquez L; Gentilini MV; Marini V; Benedetti M; Nabaes Jodar MS; Viegas M; Shayo C; Bueno CA
    Antiviral Res; 2020 Jul; 179():104817. PubMed ID: 32387475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
    Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
    Buchholz UJ; Cunningham CK; Muresan P; Gnanashanmugam D; Sato P; Siberry GK; Rexroad V; Valentine M; Perlowski C; Schappell E; Thumar B; Luongo C; Barr E; Aziz M; Yogev R; Spector SA; Collins PL; McFarland EJ; Karron RA;
    J Infect Dis; 2018 Apr; 217(9):1338-1346. PubMed ID: 29509929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.